<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-11-30</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-11-30</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>73</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>4</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ“° å…¬ä¼—å·</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
å…¨æ–°ç»†èƒæ­»äº¡æ–¹å¼Mitoxyperilysisï¼ˆçº¿ç²’ä½“æ°§åŒ–é©±åŠ¨ï¼‰è¢«å‘ç°ï¼Œä¸ºç™Œç—‡æ²»ç–—æä¾›æ–°é¶ç‚¹ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å…ç–«é€ƒé€¸ä¸è€è¯ï¼šFAM114A1åœ¨ä¸‰é˜´æ€§ä¹³è…ºç™Œä¸­å…³é”®ä½œç”¨ï¼›C1QC+å·¨å™¬ç»†èƒ-CD4+ Tç»†èƒäº’ä½œï¼›å¹²æ‰°ç´ è¯±å¯¼çš„è¡°è€CD8Tç»†èƒå½±å“å…ç–«æ²»ç–—ï¼›é¶å‘DPP7+TAMsæé«˜å…ç–«æ²»ç–—ç–—æ•ˆï¼›åŸºè´¨ç»†èƒ-å…ç–«ç»†èƒäº’ä½œç½‘ç»œï¼›é¶å‘è‚¿ç˜¤é…¸ä¸­æ¯’ã€‚<br />
- è¡°è€ä¸ç–¾ç—…æœºåˆ¶ï¼šè¡°è€ä½œä¸ºèƒ¶è´¨æ¯ç»†èƒç˜¤é¢„åé£é™©å› ç´ ï¼›è¡°è€ä¸ç–¾ç—…æœºåˆ¶ç ”ç©¶ï¼ˆè¡€ç®¡å’Œç¥ç»ç±»å™¨å®˜æ¨¡å‹ï¼‰ã€‚<br />
- ç»†èƒæ­»äº¡ä¸ä»£è°¢ï¼šçº¿ç²’ä½“NAD+è°ƒæ§çº¿ç²’ä½“è‡ªå™¬åŠç‚ç—‡ååº”ï¼›æ°¨åŸºé…¸ä»£è°¢åœ¨ç™Œç—‡ç ”ç©¶ä¸­çš„åº”ç”¨ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- ç©ºé—´å¤šç»„å­¦æ­ç¤ºç»†èƒç”Ÿæ€ä½ã€‚<br />
- å¤šç»„å­¦ï¼ˆåŒ…æ‹¬è¡¨è§‚åŸºå› ç»„ï¼‰åˆ†æé©±åŠ¨è¯ç‰©è€è¯æ€§æœºåˆ¶ã€‚<br />
- å¹²æ¹¿ç»“åˆï¼ˆç”Ÿä¿¡ä¸å®éªŒéªŒè¯ï¼‰æ¨¡å¼å¹¿æ³›åº”ç”¨äºå¤šé¢†åŸŸç ”ç©¶ï¼Œå°¤å…¶åœ¨è¯†åˆ«å…³é”®åŸºå› ã€éªŒè¯æ¨¡å‹åŠç ”ç©¶é€šè·¯æ–¹é¢ã€‚<br />
- å•ç»†èƒRNAæµ‹åºçš„å¤§è§„æ¨¡åŸºå‡†æµ‹è¯•ã€‚</p>
<h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
MHC II-restricted neoantigenç–«è‹—æˆåŠŸé€†è½¬å†·è‚¿ç˜¤çš„å…ç–«å¾®ç¯å¢ƒï¼Œå…‹æœå¯¹å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚ï¼ˆICIsï¼‰çš„è€è¯æ€§ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>è‚¿ç˜¤å…ç–«æ²»ç–—</strong>ï¼šæ¢ç´¢æ–°å‹ç–«è‹—ï¼ˆMHC II-restricted neoantigenç–«è‹—ï¼‰å’Œè¯ç‰©ï¼ˆHER3-DXdï¼‰åœ¨å†·è‚¿ç˜¤å’Œå®ä½“ç˜¤ä¸­çš„ç–—æ•ˆåŠè€è¯æœºåˆ¶ã€‚<br />
*   <strong>è‚¿ç˜¤å¾®ç¯å¢ƒä¸åŸºå› è°ƒæ§</strong>ï¼šè§£æèƒ¶åŸè›‹ç™½æ’åˆ—ã€RNAåœ¨æŸ“è‰²è´¨è°ƒæ§ä¸­çš„ä½œç”¨ã€è½¬åº§å­è°ƒæ§å…ƒä»¶çš„ç»„ç»‡ç‰¹å¼‚æ€§é™åˆ¶ï¼Œä»¥åŠCDK9åœ¨Tç»†èƒæ·‹å·´ç˜¤ä¸­çš„ä¾èµ–æ€§ã€‚<br />
*   <strong>ç™Œç—‡ä»£è°¢ä¸ä¿¡å·é€šè·¯</strong>ï¼šç ”ç©¶ç³–é…µè§£å¼‚è´¨æ€§é©±åŠ¨çš„èƒ°è…ºç™Œï¼ˆPDACï¼‰ä»£è°¢é¶å‘æ²»ç–—ï¼Œä»¥åŠé“œæŠ‘åˆ¶ATRä¸PARPæŠ‘åˆ¶å‰‚ååŒæŠ—ç™Œçš„æœºåˆ¶ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>ç©ºé—´è½¬å½•ç»„å­¦</strong>ï¼šç»“åˆèƒ¶åŸè›‹ç™½åˆ†æï¼ˆCASTAï¼‰æ­ç¤ºç»“ç›´è‚ ç™Œä¸­çš„åŸºå› ç¨‹åºã€‚<br />
*   <strong>å¤šç»„å­¦æ•´åˆ</strong>ï¼šåˆ©ç”¨RNA-seqã€ATAC-seqã€ChIP-seqã€CLAP-seqã€scRNA-seqç­‰æŠ€æœ¯æ·±å…¥ç ”ç©¶åŸºå› è¡¨è¾¾ã€æŸ“è‰²è´¨å¯åŠæ€§åŠè›‹ç™½ç»“åˆã€‚</p>
<h3>ğŸ”¬ æœŸåˆŠæ–‡ç« </h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å—å¨å°”å£«å·ï¼ˆNSWï¼‰å°†æ¶ˆé˜²å‘˜çš„ç™Œç—‡ä¿é™©è¦†ç›–èŒƒå›´æ‰©å¤§è‡³åŒ…æ‹¬æ›´å¤šç§ç±»çš„ç™Œç—‡ï¼Œè¿™æ˜¯å¯¹æ¶ˆé˜²å‘˜å¥åº·ä¿éšœçš„ä¸€é¡¹é‡å¤§è¿›å±•ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
* æ‰©å¤§ç‰¹å®šèŒä¸šæš´éœ²ç›¸å…³ç™Œç—‡çš„ä¿é™©èŒƒå›´ã€‚<br />
* æå‡æ¶ˆé˜²å‘˜å› å·¥æ‚£ç™Œçš„ç»æµå’ŒåŒ»ç–—æ”¯æŒã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
* åŸºäºæµè¡Œç—…å­¦æ•°æ®å’ŒèŒä¸šé£é™©è¯„ä¼°ï¼Œé‡æ–°ç•Œå®šäº†ä¿é™©è¦†ç›–çš„ç™Œç—‡åˆ—è¡¨ã€‚<br />
* æ”¿ç­–è°ƒæ•´æ—¨åœ¨è§£å†³æ¶ˆé˜²å‘˜èŒä¸šå¥åº·é£é™©çš„é•¿æœŸæ€§é—®é¢˜ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
é¦–æ¬¡å‘ç°è¡€æ¶²ç»†èŒäº§ç”Ÿçš„æ–°å‹åˆ†å­å…·æœ‰æ˜¾è‘—æŠ—è¡°è€æ½œåŠ›ï¼Œèƒ½æœ‰æ•ˆæŠ‘åˆ¶ç‚ç—‡ã€æ°§åŒ–åº”æ¿€å’Œèƒ¶åŸè›‹ç™½é™è§£ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è¯†åˆ«å’Œè¡¨å¾è¡€æ¶²ç»†èŒäº§ç”Ÿçš„æŠ—è¡°è€ä»£è°¢ç‰©ã€‚<br />
- è¯„ä¼°è¿™äº›åˆ†å­åœ¨æŠ‘åˆ¶è¡°è€ç›¸å…³ç‚ç—‡å’Œæ°§åŒ–åº”æ¿€ä¸­çš„ä½œç”¨ã€‚<br />
- æ¢ç´¢å…¶ä¿æŠ¤èƒ¶åŸè›‹ç™½å…å—æŸä¼¤çš„æœºåˆ¶ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- é‰´å®šå‡ºä¸€ç§æ–°å‹çš„ã€æ­¤å‰ç ”ç©¶ç”šå°‘çš„è¡€æ¶²ç»†èŒã€‚<br />
- å‘ç°å…¶äº§ç”Ÿçš„å²å“šç±»ä»£è°¢ç‰©å…·æœ‰å¤šé‡æŠ—è¡°è€æ´»æ€§ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (35æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>Cancer Immunol Immunother | 2025å¹´ä¾æ—§å¯ç”¨çš„5+è‚¿ç˜¤ç”Ÿä¿¡æ€è·¯ï¼šé¢„å+å•ç»†èƒ+bulk+å®éªŒéªŒè¯</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€cancerã€Tç»†èƒã€å•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šè¡°è€æ˜¯èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ˆGBMï¼‰æ‚£è€…ä¸è‰¯é¢„åçš„ä¸€ä¸ªå…¬è®¤é£é™©å› ç´ ï¼Œå¹¶ä¸”åŠæ•°ä»¥ä¸Šçš„GBMæ‚£è€…æ˜¯è€å¹´äººï¼Œä½†æ˜¯ç›®å‰å¯¹äºå¹´é¾„<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248976&amp;idx=1&amp;sn=0b9f66fbabeacd3de17204ecb2a0be7a" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>STTTï¼šå¸®ç™Œç»†èƒæ”¶æ•›â€œå…‰èŠ’â€ï¼å¤æ—¦å¤§å­¦/åŒæµå¤§å­¦ç­‰å›¢é˜Ÿå‘ç°ï¼ŒFAM114A1æ˜¯ä¸‰é˜´æ€§ä¹³è…ºç™Œå…ç–«é€ƒé€¸å’Œå¯¹å…ç–«æ²»ç–—è€è¯çš„å…³é”®å› å­</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå¥‡ç‚¹è‚¿ç˜¤æ¢ç§˜<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€Tç»†èƒã€ç»†èƒå› å­ã€è€è¯<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šå…¬å¸ƒä¸‰é˜´æ€§ä¹³è…ºç™Œçš„éšèº«ç§˜è¯€ï¼<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI4ODc5MDI5NA==&amp;mid=2247503632&amp;idx=1&amp;sn=553cfcb3aaa6013f4edf1f70ea14d90b" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>ç©ºé—´å¤šç»„å­¦æ­ç¤ºç»“ç›´è‚ ç™Œä¸­C1QC+å·¨å™¬ç»†èƒ-CD4+ Tç»†èƒç”Ÿæ€ä½åŠå…¶å¯¹å…ç–«æ²»ç–—çš„å¯ç¤º</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šäººä½“è›‹ç™½è´¨ç»„å¯¼èˆªè®¡åˆ’<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€Tç»†èƒã€å·¨å™¬ç»†èƒã€ç©ºé—´ç»„å­¦<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507767&amp;idx=1&amp;sn=0fbbe3fba6195da3f82f357f9376449d" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>AMLç»†èƒå¤šç»„å­¦åˆ†æå¹¶æ­ç¤ºè¡¨è§‚åŸºå› ç»„æœºåˆ¶é©±åŠ¨è¯ç‰©è€è¯æ€§çš„äº§ç”Ÿ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå•ç»†èƒå¤©åœ°<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè€è¯ã€åŸºå› ç»„ã€è¡¨è§‚åŸºå› ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šè¡€æ¶²è‚¿ç˜¤AMLè¿›è¡Œå¤šç»„å­¦åˆ†æè¯„ä¼°åŒ–ç–—è€è¯æ–°æœºåˆ¶ï¼Œç¡®å®šè¡¨è§‚é—ä¼ é‡ç¼–ç¨‹è€ŒéåŸºå› çªå˜æ˜¯è€è¯æ€§äº§ç”Ÿçš„ä¸»è¦é©±åŠ¨åŠ›ã€‚å»ç”²åŸºåŒ–è¯ç‰©å¯è¯±å¯¼ç»†èƒå‘æ›´åŸå§‹çŠ¶æ€é€†è½¬ã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&amp;mid=2247534063&amp;idx=1&amp;sn=ab2004c0c7d85e1d99cb287e2eaa5502" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>8+å¹²æ¹¿ç»“åˆæ¨¡æ¿æ–‡ç« ï¼Œç»“åˆåˆ†å‹å’Œå»ºæ¨¡è¯†åˆ«è„‚è´¨ä»£è°¢å…³é”®åŸºå› ï¼Œè¿›å±•å¢æ®–ï¼Œå‡‹äº¡ï¼Œä»£è°¢å’Œå…ç–«å¾®ç¯å¢ƒçš„å®éªŒéªŒè¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€ä»£è°¢<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504134&amp;idx=6&amp;sn=4ea8f84ee8fde511c42be4a03126f405" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>æœ€æ–°14+å¹²æ¹¿ç»“åˆSCIï¼Œä½œè€…é‰´å®šå‡ºå¹²æ‰°ç´ è¯±å¯¼çš„è¡°è€ CD8T ç»†èƒå¹¶æ­ç¤ºå…¶å¯¹å…ç–«æ²»ç–—çš„å½±å“ã€‚è¡°è€è™½è€ï¼Œä½†æ˜¯çœŸçš„ç«ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€è¡°è€ã€Tç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504134&amp;idx=4&amp;sn=b3501612bf2bb9ead6b5268594e2a367" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>10.6åˆ†éè‚¿ç˜¤å¹²æ¹¿ç»“åˆç”Ÿä¿¡ï¼Œé¶å‘ CD177 + ä¸­æ€§ç²’ç»†èƒå‡è½»ç¼ºè¡€å†çŒæ³¨æŸä¼¤ã€‚é€‚åˆåŠ¨ç‰©å»ºæ¨¡æµ‹åºæ€è·¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€æµ‹åºã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504134&amp;idx=3&amp;sn=f8d0517f9fe8929b6904909e4c0fb64d" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>å•ç»†èƒ+ç©ºè½¬+ä»£è°¢ç»„ï¼Œå…¬å¼€æ•°æ®é›†æ‰¾å‡ºäº®ç‚¹å°±èƒ½å‘1åŒº12åˆ†</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢ã€ä»£è°¢ç»„ã€å•ç»†èƒ<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248976&amp;idx=4&amp;sn=0576c1aaee3516acf4d81fa0536758b8" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>å›½å®¶ç§‘æŠ€é‡å¤§ä¸“é¡¹å°±æ”¯æŒé™¢å£«è¯¾é¢˜ç»„åšä¸€ä¸ªtcgaä»»æ„ç™Œç—‡çš„è½¬å½•ç»„å·®å¼‚åˆ†æå—ï¼Ÿï¼ˆé¥¶æ¯…éƒ½æ‡’å¾—æ€¼è¿™äº›ï¼‰</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡æŠ€èƒ½æ ‘<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€è½¬å½•ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šè®©æˆ‘æœ‰ç‚¹çº³é—·ï¼šå›½å®¶ç§‘æŠ€é‡å¤§ä¸“é¡¹å°±æ”¯æŒé™¢å£«è¯¾é¢˜ç»„åšä¸€ä¸ªtcgaä»»æ„ç™Œç—‡çš„è½¬å½•ç»„å·®å¼‚åˆ†æå—ï¼Ÿ<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&amp;mid=2247547266&amp;idx=1&amp;sn=7ae51a2a7700df86e8e82d1817078771" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>æœ€æ–°11+ç”Ÿä¿¡ï¼Œèšç„¦åŸºè´¨ç»†èƒ-å…ç–«ç»†èƒçš„äº’ä½œç½‘ç»œã€‚æœ¬æ–‡å®éªŒå®Œç¾è¯å®ç”Ÿä¿¡ç»“æœï¼Œå¹²æ¹¿ç»“åˆæ°åˆ°å¥½å¤„ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šä¸œæ™“ç”Ÿç‰©<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€ç”Ÿä¿¡<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTU2MzM2NA==&amp;mid=2247493052&amp;idx=1&amp;sn=301427e4041c0565adff83aed89c5625" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 25 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-å…¬ä¼—å·">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (36æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE275680 MHC II é™åˆ¶æ€§æ–°æŠ—åŸç–«è‹—é€†è½¬å…ç–«å¾®ç¯å¢ƒå¹¶å…‹æœå†·è‚¿ç˜¤å¯¹å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚çš„è€è¯æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€vaccineã€MHCã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xueru Song ; Chun LuSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusCold tumors are resistant to immune checkpoint inhibitors (ICIs) due to their poor T cell infiltration and immunosuppressive tumor microenvironment (TME). While the role of CD4+ T cell response in anti-tumor immunity has been emphasized, it remains unclear whether the MHC II-restricted neoantigen vaccines targeting CD4+ T cell can reverse the immune microenvironment and overcome resistance to ICIs. Here we observed an enrichment of immune inflammation-related signaling pathways in TME following administration of MHC II-restricted neoantigen vaccines, indicating their potent role in reversing immunosuppressive TME. An increase in the tumor infiltration of CD4+ T cells and CD8+ T cells, an enhancement of their effector functions, and a tendency towards exhaustion were observed, providing prerequisites for the effectiveness of ICI treatment. Furthermore, NicheNet analysis indicated an enrichment of the inhibitory immune checkpoint signaling axis PVR-TIGIT following vaccination. The combination of the vaccines and TIGIT blockade exhibited synergistic anti-tumor efficacy. Mechanistically, the combination therapy promoted the differentiation of CD8+ T cells into effector memory phenotypes while delaying their exhaustion. Our study demonstrates that MHC II-restricted neoantigen vaccines can remodel the inhibitory TME with insufficient T cell infiltration and synergistically inhibit tumor growth with TIGIT antibody, providing a novel strategy for treating cold tumors.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275680" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE311294 èƒ¶åŸè›‹ç™½æ’åˆ—å’Œç©ºé—´è½¬å½•ç»„å­¦åˆ†æ (CASTA) æ­ç¤ºäº†ä¸ç»“ç›´è‚ ç™Œä¸­èƒ¶åŸè›‹ç™½æ’åˆ—ç›¸å…³çš„åŸºå› ç¨‹åº</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€spatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Maxwell Hamilton ; Alan Simmons ; Harsimran Kaur ; Samuel Ellis ; Ken Lau ; Robert CoffeySeries Type : OtherOrganism : Homo sapiensThe use of immune checkpoint blockade is limited to the minority of colorectal cancers that are highly infiltrated by CD8+ T cells. Therefore, a method to improve CD8+ T-cell infiltration has the potential to expand the use immune checkpoint blockade to more patients. Barriers of aligned collagen surrounding tumors have been proposed as one mechanisim of CD8+ T-cell exclusion. We use 5 colorectal cancer patient samples to examine the relationship between collagen alignment and gene expression.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311294" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE299573 è†€èƒ±ç™Œé³çŠ¶åˆ†åŒ–çš„ç©ºé—´è½¬å½•ç»„å­¦</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€spatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Ryuta Watanabe ; Shunsuke Haga ; Noriyoshi Miura ; Tadahiko Kikugawa ; Takashi SaikaSeries Type : OtherOrganism : Homo sapiensWe analyze the gene expression of bladder cancer with squamous differenciarion using spatial gene expression analysis techniques (Visium HD, 10x genomics).<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299573" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE275679 RNAæµ‹åºï¼Œåˆ†æäº†ç”¨ç”Ÿç†ç›æ°´æˆ–M44ç–«è‹—æ²»ç–—çš„B16F10è·ç˜¤å°é¼ çš„æ–°é²œè‚¿ç˜¤ç»„ç»‡ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€vaccineã€sequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xueru Song ; Chun LuSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTo further reveal the immune regulatory effects of MHC II-restricted vaccines on TME, bulk RNA sequencing (bulk RNA-seq) was performed to analyze the overall immune signal transformation. Differential gene expression analysis recognized a total of 1695 upregulated and 343 downregulated genes on the M44 vaccination. Specifically, a higher expression of CD74, H2-Ab1, H2-Eb1, H2-Aa was observed in the vaccinated group, indicating the active MHC class II antigen processing and presentation in tumors. The ssGSEA method was used to quantify RNA-seq data of each sample and the GO_BP (Biological Process of Gene Ontology) term scores were calculated. The results indicated that the majority of the terms within high ssGSEA scores were related to both adaptive and innate immune-related processes.We then sorted the top 300 differently upregulated genes to generated pathway enrichment analysis and clustered the pathways into 20 categories based on functional relevance. Interestingly, the majority of categories were related to the activation of antitumor immune response, such as â€œinflammatory responseâ€ â€œleukocyte activationâ€ â€œantigen processing and presentationâ€ â€œleukocyte migrationâ€ and â€œphagocytosisâ€. Moreover, immune infiltration estimations showed increased infiltration levels of T cells, CD8+ T cells, NK cells, memory B cells and monocytes/macrophages.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275679" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE300421 RNA ä¿ƒè¿›æŸ“è‰²è´¨ç›¸å…³å‡èšä½“çš„æˆæ ¸å’Œè‡´ç™Œæ´»æ€§ [ChIP-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šregex:onco(logy|logist|gene|genic)ã€ChIP-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Krista A Budinich ; Xinyi Yao ; Chujie Gong ; Lele Song ; Michelle C Lee ; Qinglan Li ; Sylvia Tang ; Kaeli M Mathias ; Yiman Liu ; Son C Nguyen ; Eric F Joyce ; Yuanyuan Li ; Haitao Li ; Liling WanSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensAberrant chromatin-associated condensates have emerged as drivers of gene dysregulation in cancer, yet the mechanisms regulating their formation and function remain poorly understood. Mutations in the histone acetylation reader ENL, recurrent in leukemia and Wilms tumor, drive oncogenesis by inducing condensate formation at selective target loci. Here, we show that RNA promotes the nucleation, chromatin engagement, and oncogenic activity of ENL mutant condensates. Mutant ENL binds RNA via a conserved basic patch within the YEATS domain, and this interaction enhances condensate formation in vitro and in cells. Acute displacement and reassembly experiments demonstrate that interactions with local RNA transcripts facilitate condensate nucleation efficiency at endogenous target loci. Partial disruption of RNA binding preferentially impairs chromatin occupancy of ENL mutants at condensate-permissive loci, leading to reduced transcriptional bursting and target gene expression. In mouse models, disrupting RNA binding compromises mutant ENL-driven gene expression and malignant self-renewal, halting disease progression and prolonging survival. These findings uncover a previously unrecognized role of RNA in promoting the formation and oncogenic function of chromatin-associated condensate.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300421" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE300418 RNA ä¿ƒè¿›æŸ“è‰²è´¨ç›¸å…³å‡èšä½“çš„æˆæ ¸å’Œè‡´ç™Œæ´»æ€§ [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šregex:onco(logy|logist|gene|genic)ã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Krista A Budinich ; Xinyi Yao ; Chujie Gong ; Lele Song ; Michelle C Lee ; Qinglan Li ; Sylvia Tang ; Kaeli M Mathias ; Yiman Liu ; Son C Nguyen ; Eric F Joyce ; Yuanyuan Li ; Haitao Li ; Liling WanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusAberrant chromatin-associated condensates have emerged as drivers of gene dysregulation in cancer, yet the mechanisms regulating their formation and function remain poorly understood. Mutations in the histone acetylation reader ENL, recurrent in leukemia and Wilms tumor, drive oncogenesis by inducing condensate formation at selective target loci. Here, we show that RNA promotes the nucleation, chromatin engagement, and oncogenic activity of ENL mutant condensates. Mutant ENL binds RNA via a conserved basic patch within the YEATS domain, and this interaction enhances condensate formation in vitro and in cells. Acute displacement and reassembly experiments demonstrate that interactions with local RNA transcripts facilitate condensate nucleation efficiency at endogenous target loci. Partial disruption of RNA binding preferentially impairs chromatin occupancy of ENL mutants at condensate-permissive loci, leading to reduced transcriptional bursting and target gene expression. In mouse models, disrupting RNA binding compromises mutant ENL-driven gene expression and malignant self-renewal, halting disease progression and prolonging survival. These findings uncover a previously unrecognized role of RNA in promoting the formation and oncogenic function of chromatin-associated condensate.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300418" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE291608 å‰ªæ¥å¼‚æ„ä½“æ‰°åŠ¨ä¸å•ç»†èƒè½¬å½•ç»„åˆ†æç›¸ç»“åˆæ­ç¤ºäº†å¾®å¤–æ˜¾å­åœ¨ç¥ç»å‘ç”Ÿå’Œè‡ªé—­ç—‡ç›¸å…³é€šè·¯ä¸­çš„åŠŸèƒ½ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€transcriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Steven Dupas ; Guillermo Parada ; Jack Diayang Li ; Kevin Brown ; Jason Moffat ; Benjamin BlencoweSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusA major challenge of biomedical research is to assign functions to the myriad alternative RNA and protein isoforms. This challenge is particularly relevant to the mammalian nervous system, which produces complex repertoires of alternative splicing events. Here, we describe CHyMErA-seq, a platform that couples systematic deletion of exons to a single cell transcriptomics read-out, and apply this method to investigate a critical program of brain-specific microexons. Perturbation of microexons during neurogenesis reveals convergent roles in the temporal regulation of gene expression programs that direct signalling pathways and morphogenesis. We further observe microexons, including those in the Bin1, Clasp1, Gfra1, Med23, Ptprf and Ralgapb genes, that are required for the correct timing of autism-linked gene expression. Collectively, we describe a flexible system for isoform-resolution perturbation at a single cell level, together with insights into the roles of microexons in the developmental timing of neurogenesis transcriptomic signatures linked to brain disorders.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291608" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE311464 è„‘ç™Œæ‚£è€…ä½“å†…ä»£è°¢é€šé‡ä¼°ç®—çš„æ•°å­—å­ªç”Ÿæ¨¡å‹ II</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€metabolic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Baharan Meghdadi ; Wajd N. Al-Holou ; Andrew J. Scott ; Anjali Mittal ; Ningning Liang ; Sravya Palavalasa ; Abhinav Achreja ; Alexandra O'Brien ; Kathy Do ; Zhe Wu ; Jiane Feng ; Nathan R. Qi ; Vijay Tarnal ; Sriram Venneti ; C. Ryan Miller ; Jann N. Sarkaria ; Weihua Zhou ; Theodore S. Lawrence ; Costas A. Lyssiotis ; Daniel R. Wahl ; Deepak NagrathSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusRecent advancements in metabolic flux estimations in vivo are limited to preclinical models, primarily due to challenges in tissue sampling, tumor microenvironment heterogeneity, and non-steady state conditions. To address these limitations and enable flux estimation in human patients, we developed two machine learning-based frameworks. First, the digital twin framework integrates first-principles stoichiometric and isotopic simulations with convolutional neural networks to estimate fluxes in patient bulk samples. Second, the 13C-scMFA framework combines patient scRNA-seq data with 13C-isotope tracing, allowing single-cell-level flux quantification. These studies allow quantification of metabolic activity in neoplastic glioma cells, revealing frequently elevated purine synthesis and serine uptake compared to non-malignant cells. Our models also identify metabolic heterogeneity among patients and mice with brain cancer, in turn predicting treatment responses to metabolic inhibitors. Our frameworks advance in vivo metabolic flux analysis, may lead to novel metabolic therapies, and identify biomarkers for metabolism-directed therapies in patients.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311464" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE311441 äº¤æ„Ÿç¥ç»å…ƒè¿‡åº¦æ¿€æ´»é©±åŠ¨æ¯›å›Šåæ­»å’Œ T ç»†èƒè‡ªèº«ååº”æ€§ [scRNA]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šT cellã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Emily Scott-Solomon ; Shlomi Brielle ; Ya-Chieh HsuSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusStress profoundly affects health, but the mechanisms driving stress-induced tissue changes remain poorly understood. Here, we show that strong acute stress drives rapid hair loss and initiates autoimmunity. Under stress, hyperactivated sympathetic nerves release excessive norepinephrine, causing necrosis in rapidly dividing hair follicle transit-amplifying cells (HF-TACs) while sparing most hair follicle stem cells (HFSCs). This differential sensitivity to stress stems from differences in cell death genes, metabolic strategies, and calcium homeostasis. Together, these factors render HF-TACs more vulnerable to the sudden calcium surges triggered by norepinephrine. HF-TAC necrosis releases cellular debris that triggers macrophage clearance and dendritic cell activation, ultimately leading to the activation and amplification of autoreactive T cells that can attack the hair follicle. Our findings reveal mechanistically how stress causes immediate tissue damage in the highly proliferative HF-TACs via sympathetic nerve-induced necrosis, which in turn fuels the activation of a T cell-mediated response against the hair follicle.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311441" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE308506 å¤–æ˜¾å­6æˆªçŸ­çš„p53æŠ‘åˆ¶å…ˆå¤©å…ç–«ååº”ï¼Œä»è€Œä¿ƒè¿›è†€èƒ±ç™Œçš„å…ç–«é€ƒé€¸</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immune<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Chi ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusPrevious studies have reported that truncated p53 exhibits pro-tumorigenic properties; however, whether it contributes to immune evasion by influencing the immune microenvironment remains unclear.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308506" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 26 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (1æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>æ–°å—å¨å°”å£«å·æ‰©å¤§æ¶ˆé˜²å‘˜çš„ç™Œç—‡ä¿é™©è¦†ç›–èŒƒå›´</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1994573631349436416/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>éšè—çš„è¡€æ¶²åˆ†å­å±•ç°å‡ºæƒŠäººçš„æŠ—è¡°è€èƒ½åŠ›</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šaging<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists have identified new anti-aging compounds produced by a little-studied blood bacterium. These indole metabolites were able to reduce inflammation, oxidative stress, and collagen-damaging activity in skin cell cultures. Three of the compounds, including two never seen before, showed particularly strong effects. The findings hint at a surprising new source for future skin-rejuvenation therapies.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251128050514.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>10</td>
</tr>
<tr>
<td>å…ç–«</td>
<td>8</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>7</td>
</tr>
<tr>
<td>è‚¿ç˜¤</td>
<td>6</td>
</tr>
<tr>
<td>ç”Ÿä¿¡</td>
<td>5</td>
</tr>
<tr>
<td>ä»£è°¢</td>
<td>5</td>
</tr>
<tr>
<td>Tç»†èƒ</td>
<td>5</td>
</tr>
<tr>
<td>è€è¯</td>
<td>4</td>
</tr>
<tr>
<td>å•ç»†èƒ</td>
<td>4</td>
</tr>
<tr>
<td>tumor</td>
<td>4</td>
</tr>
<tr>
<td>ç™Œç—‡</td>
<td>3</td>
</tr>
<tr>
<td>åŸºå› ç»„</td>
<td>3</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>3</td>
</tr>
<tr>
<td>regex:onco(logy</td>
<td>logist</td>
</tr>
<tr>
<td>immune</td>
<td>3</td>
</tr>
<tr>
<td>çº¿ç²’ä½“</td>
<td>3</td>
</tr>
<tr>
<td>å·¨å™¬ç»†èƒ</td>
<td>2</td>
</tr>
<tr>
<td>è¡°è€</td>
<td>2</td>
</tr>
<tr>
<td>æµ‹åº</td>
<td>2</td>
</tr>
<tr>
<td>metabolic</td>
<td>2</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (25æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504134&amp;idx=2&amp;sn=5e9d3996b20ba57304352ebb9ce18a05" target="_blank" rel="noopener noreferrer">æœ€æ–°11+ç”Ÿä¿¡ï¼Œèšç„¦åŸºè´¨ç»†èƒ-å…ç–«ç»†èƒçš„äº’ä½œç½‘ç»œã€‚æœ¬æ–‡å®éªŒå®Œç¾è¯å®ç”Ÿä¿¡ç»“æœï¼Œå¹²æ¹¿ç»“åˆæ°åˆ°å¥½å¤„ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504134&amp;idx=1&amp;sn=6fc509060e55c0a3f474d3e12d0670df" target="_blank" rel="noopener noreferrer">æœ€æ–°10+ç”Ÿä¿¡ï¼Œè¯†åˆ«DPP7+TAMsï¼Œå‘ˆç°M2æåŒ–è¡¨å‹ï¼Œæ¥ç€è¿›è¡Œå®éªŒéªŒè¯ï¼é¶å‘åŸºå› å¢åŠ å…ç–«æ²»ç–—ç–—æ•ˆã€‚ç»å…¸å¹²æ¹¿ç»“åˆæ€è·¯ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503149&amp;idx=1&amp;sn=753042e3e87321055356e9d3b3b7930e" target="_blank" rel="noopener noreferrer">GWAS | Nat.Genet. | æ³›è‹±å›½ç”Ÿç‰©æ ·æœ¬åº“å…¨åŸºå› ç»„å…³è”åˆ†æå¢å¼ºäº†å¯¹ç¥–å…ˆå¯Œé›†æ•ˆåº”çš„å‘ç°ä¸è§£æèƒ½åŠ›</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507767&amp;idx=2&amp;sn=800170df90e8b9404ecf5189af0397dd" target="_blank" rel="noopener noreferrer">Nature | é‡å¡‘è‚¿ç˜¤æ¼”åŒ–æ¨¡å‹ï¼šé«˜è¾¾ 40% çš„å®¶æ—æ€§è…ºç˜¤æ€§æ¯è‚‰ç—…ï¼ˆFAPï¼‰ç™Œå‰ç—…å˜æºäºå¤šç»†èƒè°±ç³»ååŒ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkyNDI1MzE0NA==&amp;mid=2247490210&amp;idx=1&amp;sn=7d397ff4b37f9f4af10c5d5afaf87590" target="_blank" rel="noopener noreferrer">å•ç»†èƒRNAæµ‹åºçš„å¤§è§„æ¨¡åŸºå‡†æµ‹è¯•åˆ†æ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248976&amp;idx=6&amp;sn=4f2174cc605f2080465db4d378120df9" target="_blank" rel="noopener noreferrer">Scienceæ–°å‘ç°ï¼šé¶å‘â€œè‚¿ç˜¤é…¸ä¸­æ¯’â€ï¼Œæœ‰æœ›ç ´è§£æ²»ç–—è€è¯éš¾é¢˜ï¼è¿™3ä¸ªé¶ç‚¹å€¼å¾—å…³æ³¨</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247651034&amp;idx=3&amp;sn=a1994ee5088d59f6138538e4fbc5429d" target="_blank" rel="noopener noreferrer">æ­¦æ±‰å¤§å­¦å‘¨è£å®¶å›¢é˜Ÿï¼šæ­ç¤ºçº¿ç²’ä½“ NAD+ è°ƒæ§çº¿ç²’ä½“è‡ªå™¬åŠç‚ç—‡ååº”çš„æ–°æœºåˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzMzY5NDk3NA==&amp;mid=2247493579&amp;idx=1&amp;sn=86bde006839fef8feaa47edde87e9d54" target="_blank" rel="noopener noreferrer">è‚ é“é‡Œçš„â€œéšå½¢å†…é¬¼â€ï¼šNatureå­åˆŠæ­ç§˜550ç§ç»†èŒé…¶å¦‚ä½•â€œå¤æ´»â€è‡´ç™Œæ¯’ç´ ï¼ŒåŠ é€Ÿè‚ ç™Œæ¶åŒ–ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247791008&amp;idx=3&amp;sn=c1330af4361f191988b31a125cb6bae6" target="_blank" rel="noopener noreferrer">åˆ˜å…‰æ…§å›¢é˜Ÿå»ºç«‹è¡€ç®¡å’Œç¥ç»ç±»å™¨å®˜æ¨¡å‹ï¼Œæ­ç¤ºäººç±»è¡°è€ä¸ç–¾ç—…æœºåˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247791008&amp;idx=1&amp;sn=fce45123076c1cc48b67a868ed5a2981" target="_blank" rel="noopener noreferrer">ä¸­å›½åšåä¸€ä½œCellè®ºæ–‡ï¼šå‘ç°å…¨æ–°ç»†èƒæ­»äº¡æ–¹å¼â€”â€”Mitoxyperilysisï¼Œç”±çº¿ç²’ä½“æ°§åŒ–é©±åŠ¨ï¼Œå¯ç”¨äºç™Œç—‡æ²»ç–—</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUzMTEwODk0Ng==&amp;mid=2247538330&amp;idx=1&amp;sn=81e25cd5e689688ca70b11b4dc7a1524" target="_blank" rel="noopener noreferrer">åŸºäºæ·±åº¦å­¦ä¹ çš„å•ç»†èƒæ•´åˆæ–¹æ³•çš„åŸºå‡†ç ”ç©¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzYyNDMwNjg3Nw==&amp;mid=2247484123&amp;idx=1&amp;sn=fc15ecb0d3cd1611a3b4e4dcafb9e4ce" target="_blank" rel="noopener noreferrer">ç»´ç”Ÿç´ Dä½“å†…ä»£è°¢è¿‡ç¨‹ï¼ˆå»ºè®®æ”¶è—ï¼‰</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkyNzcxMjEyMg==&amp;mid=2247498087&amp;idx=1&amp;sn=ca6d5718d6ca7c40bc99386f0d1e3ec7" target="_blank" rel="noopener noreferrer">è¿™ç¯‡çš„èªæ˜ä¹‹å¤„é€‚åˆå­¦ï¼é â€œTFAM-æ ¸å¿ƒåŸºå› -é€šè·¯â€è½´æ­æ¡†æ¶ï¼Œå°±èƒ½å¿«é€Ÿç§¯ç´¯å›½è‡ªç„¶å‰æœŸæ•°æ®ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkyNzcxMjEyMg==&amp;mid=2247498125&amp;idx=1&amp;sn=664cdf46c01722b58630b1e9e8ded939" target="_blank" rel="noopener noreferrer">è°è¿˜åœ¨æ‰¾å·¨å™¬ç»†èƒæ–°æ€è·¯ï¼ŸIF:10.1å¹¿å·å¤§å­¦å‘ç°PGE2-EP4-C/EBPÎ²æ­£åé¦ˆå›è·¯</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504134&amp;idx=5&amp;sn=37c1d55952c0061de6e8def2fae00045" target="_blank" rel="noopener noreferrer">æ°¨åŸºé…¸ä»£è°¢æ˜¯çœŸçš„ç«ï¼Œå¹²æ¹¿ç»“åˆè½»æ¾å‘7.5åˆ†2åŒºæ–‡ç« ã€‚ç°åœ¨ä¸‹æ‰‹è¿˜ä¸æ™šï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzk3NTY2NDk1Nw==&amp;mid=2247488385&amp;idx=3&amp;sn=550caca700ce0cd0ed2487e919aebcc8" target="_blank" rel="noopener noreferrer">æ–©è·157é¡¹èµ„åŠ©çš„DNAç”²åŸºåŒ–ï¼šæœºåˆ¶å¥—è·¯è§£æï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503149&amp;idx=2&amp;sn=99c18a89b3f662b8ecf9c14a8ba9c7ed" target="_blank" rel="noopener noreferrer">åŸºå› ç»„ | Nature | åŸºäºå››ä»£å®¶ç³»å‚è€ƒçš„äººç±»æ–°ç”Ÿçªå˜ç‡</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248976&amp;idx=5&amp;sn=70016cf9dd0fb45085d35d7933e102f0" target="_blank" rel="noopener noreferrer">é›†æˆæœºå™¨å­¦ä¹ æ‰“é€šè‚¿ç˜¤é¢„åæ¨¡å‹çš„â€œæœ€åä¸€å…¬é‡Œâ€----2025å¤šé¡¹ç ”ç©¶æ·±åº¦è§£æ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248976&amp;idx=2&amp;sn=a310f32ca452eab51495da301b50353f" target="_blank" rel="noopener noreferrer">èƒ†ç®¡ç™Œæ²»ç–—é‡å¤§çªç ´ï¼šé¶å‘PARGè°ƒæ§Hippoï¼ŒåŒ–ç–—ã€å…ç–«åŒå¢æ•ˆ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656511123&amp;idx=3&amp;sn=dd1fccb9836762853795088ad290f940" target="_blank" rel="noopener noreferrer">æŠ‘åˆ¶è‡ªå™¬ï¼å—äº¬ä¸­åŒ»è¯å¤§å­¦/å“ˆå°”æ»¨åŒ»ç§‘å¤§å­¦é™„å±è‚¿ç˜¤åŒ»é™¢åˆä½œå‘æ–‡ï¼šä¹³è…ºç™Œæ²»ç–—æ–°æ–¹æ³•</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656511123&amp;idx=1&amp;sn=9f0ae70ea9742424557473005bbb49c1" target="_blank" rel="noopener noreferrer">çªç ´æŠ€æœ¯ç“¶é¢ˆï¼ä¸­ç§‘é™¢å¶æ˜äº®å›¢é˜Ÿå¼€å‘æ–°å‹è›‹ç™½è´¨ç»„å­¦æ–¹æ³•é¦–æ¬¡åœ¨æ´»ç»†èƒä¸­åŸä½ã€é«˜é€šé‡åœ°è§£æè¯ç‰©ä½œç”¨æ—©æœŸåˆ†å­äº‹ä»¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzMzY5NDk3NA==&amp;mid=2247493603&amp;idx=1&amp;sn=11c96e6abde077c0b56d8d625a848c46" target="_blank" rel="noopener noreferrer">Cellé‡ç£…å®šä¹‰ï¼2025å¹´é¦–ä¸ªæ–°å‹ç»†èƒæ­»äº¡æ–¹å¼â€œMitoxyperilysisâ€è¯ç”Ÿï¼šçº¿ç²’ä½“æ°§åŒ–å‘¨äº¡</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5MjcxNzg1NA==&amp;mid=2247489040&amp;idx=2&amp;sn=b1320c7018df0408c89cd2aa6446a140" target="_blank" rel="noopener noreferrer">ç©ºé—´èšç±»åˆ†æä¹‹cellcharter</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247791008&amp;idx=2&amp;sn=047aba4f67576cf70e24da45a6fff22a" target="_blank" rel="noopener noreferrer">èµ«æ·é™¢å£«å›¢é˜Ÿè¯å®ï¼Œé“œæ­»äº¡å¯å…‹æœè‚ºç™Œé¶å‘æ²»ç–—è€è¯æ€§</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxODY4NDEwMA==&amp;mid=2247490198&amp;idx=1&amp;sn=4feefaa6c1861236fdf5e724ee59f748" target="_blank" rel="noopener noreferrer">Nature Metabolismæ­ç¤ºèŠ³é¦™æ°¨åŸºé…¸ä»£è°¢ç‰©åœ¨é¢„é˜²è‚¥èƒ–ä¸­çš„å…³é”®ä½œç”¨</a></li>
</ul>
</div>
</details>

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (26æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303338" target="_blank" rel="noopener noreferrer">GSE303338 ç³–é…µè§£å¼‚è´¨æ€§é©±åŠ¨èƒ°è…ºç™Œä»£è°¢é¶å‘æ²»ç–—</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296515" target="_blank" rel="noopener noreferrer">GSE296515 A Natural Cyclic Peptide Enhances Cytotoxic Th9 Differentiation and Antitumor Immunity (ATACseq)</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295054" target="_blank" rel="noopener noreferrer">GSE295054 å¤©ç„¶ç¯çŠ¶è‚½å¢å¼ºç»†èƒæ¯’æ€§ Th9 åˆ†åŒ–å’ŒæŠ—è‚¿ç˜¤å…ç–«</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE246085" target="_blank" rel="noopener noreferrer">GSE246085 é“œæŠ‘åˆ¶ ATR å¹¶ä¸ PARP æŠ‘åˆ¶å‰‚äº§ç”ŸååŒä½œç”¨ï¼ˆRNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311829" target="_blank" rel="noopener noreferrer">GSE311829 AP-1 ä»‹å¯¼ç»†èƒé€‚åº”å’Œè®°å¿†å½¢æˆ [ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311827" target="_blank" rel="noopener noreferrer">GSE311827 AP-1 ä»‹å¯¼ç»†èƒé€‚åº”å’Œè®°å¿†å½¢æˆ [æ‰¹é‡ RNA æµ‹åº]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311825" target="_blank" rel="noopener noreferrer">GSE311825 AP-1ä»‹å¯¼ç»†èƒé€‚åº”å’Œè®°å¿†å½¢æˆ[scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310423" target="_blank" rel="noopener noreferrer">GSE310423 ä¹³è…ºç™Œæ‚£è€…æ¥æºçš„å¼‚ç§ç§»æ¤ä¸­å¯¹å¸•å¦¥ç å•æŠ—å¾·é²æ›¿åº·ï¼ˆHER3-DXdï¼‰é•¿æœŸååº”çš„å†³å®šå› ç´ ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310422" target="_blank" rel="noopener noreferrer">GSE310422 ä¹³è…ºç™Œæ‚£è€…æ¥æºå¼‚ç§ç§»æ¤ä¸­å¸•å¦¥ç å•æŠ—å¾·é²æ›¿åº·ï¼ˆHER3-DXdï¼‰é•¿æœŸååº”çš„å†³å®šå› ç´  [NanoString]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307574" target="_blank" rel="noopener noreferrer">GSE307574 ä¹³è…ºç™Œæ‚£è€…æ¥æºå¼‚ç§ç§»æ¤æ¨¡å‹ä¸­å¸•å¦¥ç å•æŠ—å¾·é²æ›¿åº·ï¼ˆHER3-DXdï¼‰é•¿æœŸç–—æ•ˆçš„å†³å®šå› ç´ </a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300420" target="_blank" rel="noopener noreferrer">GSE300420 RNA ä¿ƒè¿›æŸ“è‰²è´¨ç›¸å…³å‡èšä½“çš„æˆæ ¸å’Œè‡´ç™Œæ´»æ€§ [CLAP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298498" target="_blank" rel="noopener noreferrer">GSE298498 è½¬åº§å­è¡ç”Ÿè°ƒæ§å…ƒä»¶çš„ç»„ç»‡ç‰¹å¼‚æ€§é™åˆ¶ä¿æŠ¤ç»†èƒç±»å‹ç‰¹æ€§ [ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298495" target="_blank" rel="noopener noreferrer">GSE298495 è½¬åº§å­è¡ç”Ÿè°ƒæ§å…ƒä»¶çš„ç»„ç»‡ç‰¹å¼‚æ€§é™åˆ¶ä¿æŠ¤ç»†èƒç±»å‹ç‰¹æ€§ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296537" target="_blank" rel="noopener noreferrer">GSE296537 CDK9 æ˜¯ GATA-3 é©±åŠ¨å’Œ MCL-1 éä¾èµ–æ€§ T ç»†èƒæ·‹å·´ç˜¤çš„ä¾èµ–å› å­ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296506" target="_blank" rel="noopener noreferrer">GSE296506 CDK9 æ˜¯ GATA-3 é©±åŠ¨å’Œ MCL-1 éä¾èµ–æ€§ T ç»†èƒæ·‹å·´ç˜¤çš„ä¾èµ–åŸºå›  [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291610" target="_blank" rel="noopener noreferrer">GSE291610 å‰ªæ¥å¼‚æ„ä½“æ‰°åŠ¨ç»“åˆå•ç»†èƒè½¬å½•ç»„åˆ†ææ­ç¤ºå¾®å¤–æ˜¾å­åœ¨ç¥ç»å‘ç”Ÿå’Œè‡ªé—­ç—‡ç›¸å…³é€šè·¯ä¸­çš„åŠŸèƒ½ [snRNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282088" target="_blank" rel="noopener noreferrer">GSE282088 å‰åˆ—è…ºç´  E2-EP2/EP4 ä¿¡å·è¯±å¯¼è‚¿ç˜¤æµ¸æ¶¦æ€§ Treg è¡¨å‹ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [iTreg]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282087" target="_blank" rel="noopener noreferrer">GSE282087 å‰åˆ—è…ºç´  E2-EP2/EP4 ä¿¡å·ä¼ å¯¼è¯±å¯¼è‚¿ç˜¤æµ¸æ¶¦æ€§ Treg è¡¨å‹ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [TITreg]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282086" target="_blank" rel="noopener noreferrer">GSE282086 å‰åˆ—è…ºç´  E2-EP2/EP4 ä¿¡å·ä¼ å¯¼è¯±å¯¼è‚¿ç˜¤æµ¸æ¶¦æ€§ Treg è¡¨å‹ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [nTreg]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248839" target="_blank" rel="noopener noreferrer">GSE248839 çµé•¿ç±»åŠ¨ç‰©è¿›åŒ–è¿‡ç¨‹ä¸­ XIST è°ƒæ§ç½‘ç»œçš„å¹¿æ³›é‡å¡‘ [ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248837" target="_blank" rel="noopener noreferrer">GSE248837 çµé•¿ç±»åŠ¨ç‰©è¿›åŒ–è¿‡ç¨‹ä¸­ XIST è°ƒæ§ç½‘ç»œçš„å¹¿æ³›é‡å¡‘ [Capture Hi-C]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE246893" target="_blank" rel="noopener noreferrer">GSE246893 é“œæŠ‘åˆ¶ ATR å¹¶ä¸ PARP æŠ‘åˆ¶å‰‚äº§ç”ŸååŒä½œç”¨ï¼ˆDTP æ¨¡å‹ RNA-seq å’Œ Ola-ATRi-EC cGAS-STING RNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311382" target="_blank" rel="noopener noreferrer">GSE311382 äººç±»å°èƒ¶è´¨ç»†èƒåœ¨ä½“å†…å¯¹Î²-æ·€ç²‰æ ·è›‹ç™½ã€tauè›‹ç™½ä»¥åŠé˜¿å°”èŒ¨æµ·é»˜ç—…ç—…ç†çš„è”åˆä½œç”¨è¡¨ç°å‡ºä¸åŒçš„ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311304" target="_blank" rel="noopener noreferrer">GSE311304 HIV Nef æ”¾å¤§æœºæ¢°å¼‚è´¨æ€§ä»¥ä¿ƒè¿›å…ç–«é€ƒé€¸</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311248" target="_blank" rel="noopener noreferrer">GSE311248 æ³›ç´ ç‰¹å¼‚æ€§è‚½é…¶32ç¨³å®šYAPå¹¶ä¿ƒè¿›ä¸‰é˜´æ€§ä¹³è…ºç™Œè¿›å±•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311236" target="_blank" rel="noopener noreferrer">GSE311236 è‚¥å¤§ç»†èƒ CRFR1 é€šè¿‡ MAPK/SPHK1 ä¿¡å·é€šè·¯ä¿ƒè¿›èƒ°è…ºç™Œç–¼ç—›</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-29 21:33</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>